Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
S5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical Trials
Michael Charlton joins Jörn Schattenberg, Louise Campbell, and Roger Green for a far-reaching conversation that covers ways Rezdiffra is already impacting MASH patient treatment, exciting recent studies and broader issues in clinical trial recruitment.
00:00:00 - Surf's Up: Season 5 Episode 11
Opening comments from the panel, including brief quotes taken directly from the episode.
00:02:32 - Introduction
Opening comments (re)introducing listeners to Michael Charlton
00:04:34 - Groundbreakers
Each panelist shares one piece of good news from the previous week.
00:06:56 - Impact of Rezdiffra launch on Michael's clinic
Michael hails Rezd...
S5 - E10 - Lessons And Insights On Using Basic EHR Data To Screen For Target MASLD Patients
This episode is a follow-up to Season 4, Episode 5, where we met Tim Jobson. His company, Predictive Health Intelligence (PHI), takes a unique approach to identifying and monitoring MASLD patients using basic EHR data and analytics. This session explores PHI's work over the past years and considers implications for several liver-related health challenges.
00:00:00 - Surf's Up: Season 5 Episode 10
Opening comments from the panel, including brief quotes taken directly from the episode.
00:02:04 - Introduction and Groundbreaker
Each panelist shares one piece of good news from the previous week.
00:07:02 - New projects from Tim
S5 - E9.6 - From The Vault: An Earlier Look At Screening In The Clinical Care Pathway
This conversation comes from our coverage of The EASL Congress, 2023, when Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger Green to consider primary care screening at the top of the Clinical Care Pathway. The original conversation had a robust write-up:
Ian starts this conversation by pointing to unmet needs in the primary care setting for disease identification. He refers to a related presentation of interest from Vincent Wong titled A clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomized co...
S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers
This conversation focuses on how the need for biomarkers will evolve in an era of in-office screening and MASH drugs and ends with answers to Roger Green's closing question.
Hannes Hagstrom starts this conversation by noting that one challenge as MASH drugs become available involves knowing when to discontinue or add to therapy since, as he points out, Rezdiffra will not be efficacious for all patients. This leads Jörn Schattenberg to the need for predictive biomarkers that will be specific to drugs or modes of action. These have not been studied much to date. Jörn is...
S5 - E9.4 - In-office MASLD Screening and the Clinical Care Pathway
This conversation explores the implications of increased access to economically viable in-office screening, particularly when primary care practices begin to use the new scanning devices.
Roger Green begins this conversation by recalling a concern Naim Alkhouri expressed during S4 E50.3, that primary care reliance on FIB-4 can flood the pathways with many “wrong” patients, which might lead to confusion within the channels. Hannes Hagstrom describes a role for primary care at the top of the funnel if practitioners have clear guidance and training. Roger suggests this approach will make primary care providers triagists. The group agrees as long...
S5 - E9.3 - How Will Increased Access To In-Office Scanning Improve MASLD Therapy:
This conversation centers around the different kinds of impact that in-office scanning can have on MASLD therapy, both in terms of improved prognostics and better overall outcomes.
Roger Green starts by suggesting that the recent commercialization of a second VCTE in the U.S. (specifically, Hepatoscope from e-Scopics), coupled with increased promotion of the scanning device Velacur from Sonic Incytes, will increase education and promotion dramatically and lead to significant increases in patients scanned and scan frequency. I then note the downside to this issue: increased presence of scanning devices, coupled with the fact that FDA approved R...
S5 - E9.2 - VCTE Studies Demonstrate That Multiple Nutrition Interventions Can Support MASLD Patients
This conversation explores why different nutrition interventions might help MASLD patients improve their overall liver health and what lessons treaters and researchers can learn from this.
It starts with Louise Campbell discussing a recent publication of a pilot study from Armandi et al. (including Jörn Schattenberg as a co-author) evaluating the ability of short-term dietary gluten reduction to reduce metabolic dysfunction as measured in CAP (controlled attenuation parameter) scores. The study shows that even a short-term intervention can have a meaningful impact. The results confirm Louise’s experience with sugar-rich foods and suggest that several different diet...
S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD
This conversation focuses on the role of VCTE in diagnosing, staging and treating MASLD patients, both in terms of prognostic ability of VCTE when compared to biopsy and separately as a therapeutic adjunct.
It starts with Hannes Hagstrom and Jörn Schattenberg discussing a study from Vincent Wong and a large group of co-authors, including Hannes,, that compares the abilities or VCTE and biopsy to predict outcomes. After Hannes mentions the studies and makes the key point that VCTE might be sufficient to predict the risk of outcomes in clinical trials or other events, Jörn describes th...
S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring
Hannes Hagstrom joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss recent research panelists have conducted. This content-dense conversation focuses initially on the impact of VCTE and other forms of in-office monitoring and branches out from there.
00:00:00 - Surf's Up: Season 5 Episode 9
Opening comments from the panel, including brief quotes taken directly from the episode.
00:02:04 - Introduction and groundbreaker
Each panelist shares one piece of good news from the previous week.
00:06:02 - Introducing Topic
Roger invites panelists to share research they either participated in over the past couple o...
S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials
With Louise Campbell and Jörn Schattenberg both on Easter Week vacations, Fatty Liver Alliance Founder Mike Betel joins Roger Green to continue a brief conversation they began in a post from the Fatty Liver Alliance last weekend. This conversation focuses largely on how patient incentives to participate in MASH clinical trials might need to change now that Rezdiffra is approved.
00:00:00 - Introduction
Roger explains why Louise and Jörn are not available for this conversation and welcomes Mike to a dialogue on issues they are considering in the aftermath of Liver Forum 16.
00:01:22 - The...
